These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22008655)

  • 1. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
    Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
    AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
    Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
    Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.
    Sax PE; Sloan CE; Schackman BR; Grant PM; Rong J; Zolopa AR; Powderly W; Losina E; Freedberg KA;
    HIV Clin Trials; 2010; 11(5):248-59. PubMed ID: 21126955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis.
    Ciaranello AL; Myer L; Kelly K; Christensen S; Daskilewicz K; Doherty K; Bekker LG; Hou T; Wood R; Francke JA; Wools-Kaloustian K; Freedberg KA; Walensky RP
    PLoS One; 2015; 10(3):e0117751. PubMed ID: 25756498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care.
    Farnham PG; Gopalappa C; Sansom SL; Hutchinson AB; Brooks JT; Weidle PJ; Marconi VC; Rimland D
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):183-9. PubMed ID: 23615000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic Review.
    Ward T; Sugrue D; Hayward O; McEwan P; Anderson SJ; Lopes S; Punekar Y; Oglesby A
    J Manag Care Spec Pharm; 2020 Feb; 26(2):104-116. PubMed ID: 32011956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated direct costs of medical care for HIV-infected patients within a regional population from 2006 to 2017.
    Krentz HB; Vu Q; Gill MJ
    HIV Med; 2020 May; 21(5):289-298. PubMed ID: 31852032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
    Krentz HB; Gill MJ
    HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.
    Yazdanpanah Y; Goldie SJ; Losina E; Weinstein MC; Lebrun T; Paltiel AD; Seage GR; Leblanc G; Ajana F; Kimmel AD; Zhang H; Salamon R; Mouton Y; Freedberg KA
    Antivir Ther; 2002 Dec; 7(4):257-66. PubMed ID: 12553480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
    Schackman BR; Freedberg KA; Weinstein MC; Sax PE; Losina E; Zhang H; Goldie SJ
    Arch Intern Med; 2002 Nov; 162(21):2478-86. PubMed ID: 12437408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa.
    Walker SM; Cox E; Revill P; Musiime V; Bwakura-Dangarembizi M; Mallewa J; Cheruiyot P; Maitland K; Ford N; Gibb DM; Walker AS; Soares M;
    J Int AIDS Soc; 2020 Mar; 23(3):e25469. PubMed ID: 32219991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.
    Hyle EP; Jani IV; Lehe J; Su AE; Wood R; Quevedo J; Losina E; Bassett IV; Pei PP; Paltiel AD; Resch S; Freedberg KA; Peter T; Walensky RP
    PLoS Med; 2014 Sep; 11(9):e1001725. PubMed ID: 25225800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
    Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
    Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study.
    Scott CA; Iyer HS; McCoy K; Moyo C; Long L; Larson BA; Rosen S
    BMC Public Health; 2014 Mar; 14():296. PubMed ID: 24684772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.